Association between sidedness and survival among chemotherapy refractory metastatic colorectal cancer patients treated with trifluridine/tipiracil or regorafenib.

Kai-Yuan HsiaoHsin-Pao ChenKun-Ming RauKuang-Wen LiuBen-Chang ShiaWei-Shan ChangHao-Yun LiangMeng-Che Hsieh

Published in: The oncologist (2024)

TAS-102 first provided a better survival benefit in chemotherapy refractory patients with mCRC across all sidedness. Further prospective studies are warranted to validate our conclusions.

Keyphrases

metastatic colorectal cancer
locally advanced
free survival
squamous cell carcinoma
rectal cancer
chemotherapy induced
radiation therapy